Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

AI Chatbot Deployed To Target Drug Resistance

Scientists have developed an AI chatbot similar to ChatGPT to help governments devise effective policies for battling drug resistance.

January 13, 2025

Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating

September 4, 2024

The Endpoints Slack interview: Cellino CEO Nabiha Saklayen on cell therapy’s future, Elon Musk and time travel

Nabiha Saklayen founded Cellino Biotech just as she was finishing her PhD in physics at Harvard in 2017, while she was still in her 20s.

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.